Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Cellectar Biosciences, Inc.
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
Emory University
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Baylor College of Medicine
Seattle Children's Hospital
Dana-Farber Cancer Institute
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Seattle Children's Hospital
Seattle Children's Hospital
Taipei Medical University
Pfizer